Key result
BNT162b2 vaccination linked to ~372% higher carditis risk after a third dose, unlike CoronaVac.
Why the study?
Large-scale comparative research evaluating carditis risk after a third dose and after inactivated covid-19 vaccination was limited.
Does BNT162b2 or CoronaVac covid-19 vaccination increase the risk of carditis in vaccinated individuals?
Case-Control
Does BNT162b2 or CoronaVac covid-19 vaccination increase the risk of carditis in vaccinated individuals?
BNT162b2 mRNA vaccination is associated with an increased risk of carditis within 28 days across all three doses, particularly in young males, whereas the inactivated CoronaVac vaccine shows no significant risk increase.
Answers are grounded in this paper and cite their sources.
BNT162b2-associated carditis risk in observational data warrants surveillance; leaves open causal confirmation and vaccine-specific risk-benefit comparisons.
BackgroundLarge-scale comparative research exploring the risk after the third dose and after inactivated covid-19 vaccination is limited. This study aimed to assess the risk of carditis following three doses of BNT162b2 or CoronaVac.MethodsWe conducted a self-controlled case series (SCCS) and a case–control study using electronic health and vaccination records in Hong Kong. Carditis incidents within 28 days of covid-19 vaccination were included as cases. In the case–control study, up to 10 hospitalized controls were selected with stratified probability sampling by age, sex, and hospital admission (±1 day). The incidence rate ratios (IRRs) were reported from conditional Poisson regressions for SCCS, and adjusted odds ratios (ORs) were reported from multivariable logistic regressions.FindingsA total of 8,924,614 doses of BNT162b2 and 6,129,852 doses of CoronaVac were administered from February 2021 to March 2022. The SCCS detected increased carditis risks after BNT162b2: 4.48 (95%confidence interval [CI]:2.99–6.70] in 1–14 days and 2.50 (95%CI:1.43–4.38) in 15–28 days after first dose; 10.81 (95%CI:7.63–15.32) in 1–14 days and 2.95 (95%CI:1.82–4.78) in 15–28 days after second dose; 4.72 (95%CI:1.40–15.97) in 1–14 days after third dose. Consistent results were observed from the case–control study. Risks were specifically found in people aged below 30 years and males. No significant risk increase was observed after CoronaVac in all primary analyses.InterpretationsWe detected increased carditis risks within 28 days after all three doses of BNT162b2 but the risk after the third doses were not higher than that of the second dose when compared with baseline period. Continuous monitoring of carditis after both mRNA and inactivated covid-19 vaccines is needed.Funding: This study was funded by Hong Kong Health Bureau (COVID19F01).
No takes yet. Share an insight, caveat, or question.
Fan et al. (2023) conducted a case-control in Carditis. BNT162b2 or CoronaVac covid-19 vaccination vs. Baseline period or hospitalized controls was evaluated on Carditis incidents within 28 days of vaccination (IRR 4.72, 95% CI 1.40-15.97). BNT162b2 vaccination increased carditis risk within 28 days after all three doses, with an IRR of 4.72 1-14 days after the third dose, while CoronaVac showed no significant risk.
Synapse has enriched 10 related papers. Consider them for comparative context: